Normal Brain and Brain Tumor ADC: Changes Resulting From Variation of Diffusion Time and/or Echo Time in Pulsed-Gradient Spin Echo Diffusion Imaging

Jens Johansson; Kerstin Lagerstrand; Isabella M Björkman-Burtscher; Mats Laesser; Hanna Hebelka; Stephan E Maier

doi:10.1097/RLI.0000000000001081

Normal Brain and Brain Tumor ADC: Changes Resulting From Variation of Diffusion Time and/or Echo Time in Pulsed-Gradient Spin Echo Diffusion Imaging

Invest Radiol. 2024 Apr 9. doi: 10.1097/RLI.0000000000001081. Online ahead of print.

Authors

Jens Johansson¹, Kerstin Lagerstrand, Isabella M Björkman-Burtscher, Mats Laesser, Hanna Hebelka, Stephan E Maier

Affiliation

¹ From the Department of Radiology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden (J.J., I.M.B.-B., M.L., H.H., S.E.M.); Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden (K.L.); Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden (J.J., K.L.); Department of Radiology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden (I.M.B.-B., M.L., H.H.); and Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.E.M.).

PMID: 38587357
DOI: 10.1097/RLI.0000000000001081

Abstract

Objectives: Increasing gradient performance on modern magnetic resonance imaging scanners has profoundly reduced the attainable diffusion and echo times for clinically available pulsed-gradient spin echo (PGSE) sequences. This study investigated how this may impact the measured apparent diffusion coefficient (ADC), which is considered an important diagnostic marker for differentiation between normal and abnormal brain tissue and for therapeutic follow-up.

Materials and methods: Diffusion time and echo time dependence of the ADC were evaluated on a high-performance 3 T magnetic resonance imaging scanner. Diffusion PGSE brain scans were performed in 10 healthy volunteers and in 10 brain tumor patients using diffusion times of 16, 40, and 70 ms, echo times of 60, 75, and 104 ms at 3 b-values (0, 100, and 1000 s/mm 2 ), and a maximum gradient amplitude of 68 mT/m. A low gradient performance system was also emulated by reducing the diffusion encoding gradient amplitude to 19 mT/m. In healthy subjects, the ADC was measured in 6 deep gray matter regions and in 6 white matter regions. In patients, the ADC was measured in the solid part of the tumor.

Results: With increasing diffusion time, a small but significant ADC increase of up to 2.5% was observed for 6 aggregate deep gray matter structures. With increasing echo time or reduced gradient performance, a small but significant ADC decrease of up to 2.6% was observed for 6 aggregate white matter structures. In tumors, diffusion time-related ADC changes were inconsistent without clear trend. For tumors with diffusivity above 1.0 μm 2 /ms, with prolonged echo time, there was a pronounced ADC increase of up to 12%. Meanwhile, for tumors with diffusivity at or below 1.0 μm 2 /ms, no change or a reduction was observed. Similar results were observed for gradient performance reduction, with an increase of up to 21%. The coefficient of variation determined in repeat experiments was 2.4%.

Conclusions: For PGSE and the explored parameter range, normal tissue ADC changes seem negligible. Meanwhile, observed tumor ADC changes can be relevant if ADC is used as a quantitative biomarker and not merely assessed by visual inspection. This highlights the importance of reporting all pertinent timing parameters in ADC studies and of considering these effects when building scan protocols for use in multicenter investigations.